Herbal medicinal product: Ribis nigri folium, Ribes nigrum L., P: Draft published
Submitted by Anonymous (not verified) on 16 February 2026 - 7:53
Herbal medicinal product: Ribis nigri folium, Ribes nigrum L., P: Draft published
Draft European Union herbal monograph on Ribes nigrum L., folium - Revision 2
Submitted by Anonymous (not verified) on 16 February 2026 - 7:53
Draft European Union herbal monograph on Ribes nigrum L., folium - Revision 2
Summary of opinion: Suvaxyn PRRS MLV, 12/02/2026 Positive
Submitted by Anonymous (not verified) on 13 February 2026 - 15:00
Summary of opinion: Suvaxyn PRRS MLV, 12/02/2026 Positive
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 February 2026
Submitted by Anonymous (not verified) on 13 February 2026 - 15:00
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 February 2026
Summary of opinion: Bluevac BTV (previously Bluevac BTV8), 12/02/2026 Positive
Submitted by Anonymous (not verified) on 13 February 2026 - 15:00
Summary of opinion: Bluevac BTV (previously Bluevac BTV8), 12/02/2026 Positive
Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)
Submitted by Anonymous (not verified) on 13 February 2026 - 14:57
Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)
Highlights - 6th EMA-AESGP bilateral meeting
Submitted by Anonymous (not verified) on 13 February 2026 - 14:25
Highlights - 6th EMA-AESGP bilateral meeting
Medicinal products for human use: monthly figures - January 2026
Submitted by Anonymous (not verified) on 13 February 2026 - 14:21
Medicinal products for human use: monthly figures - January 2026
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
Submitted by Anonymous (not verified) on 13 February 2026 - 11:30
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026
EMA recommends withdrawal of marketing authorisations for levamisole medicines
Submitted by Anonymous (not verified) on 13 February 2026 - 11:29
EMA recommends withdrawal of marketing authorisations for levamisole medicines